The activation of AXL receptor tyrosine kinase (AXL) and the concomitant EMT engender resistance to EGFR-targeting therapy in non-small cell lung carcinoma (NSCLC)[37]. This evidence concerns the gene AXL and non-small cell lung carcinoma.